Pelizaeus-Merzbacher disease is a rare inherited disorder that affects the brain and spinal cord, primarily impacting males. This condition disrupts the formation of myelin, the protective covering around nerve fibers, leading to progressive neurological challenges that affect movement, coordination, and development.
Epidemiology
Pelizaeus-Merzbacher disease stands as one of the rarer conditions within the group of leukodystrophies. The disease primarily affects males due to its genetic inheritance pattern. In the United States, experts estimate that approximately 1 in 200,000 to 500,000 males are affected by this condition, though some sources suggest the incidence could be as high as 1.9 per 100,000 male births.[1][2]
The worldwide incidence of Pelizaeus-Merzbacher disease ranges between 1 per 90,000 to 1 per 750,000 live births, making it a relatively rare condition even when compared to other leukodystrophies. The disease occurs much less frequently in females due to the way it is inherited, and when females do develop symptoms, they tend to be milder or may not appear at all.[3]
This unequal distribution between sexes is directly related to the disease’s genetic mechanism. Because males have only one X chromosome, they are more vulnerable to developing the full range of symptoms when that chromosome carries the genetic mutation. Females, having two X chromosomes, often have a normal copy of the gene that can compensate for the defective one, providing some protection against the disease.[2]
Causes
Pelizaeus-Merzbacher disease is caused by mutations in a specific gene called PLP1, which stands for proteolipid protein 1. This gene is located on the long arm of the X chromosome at a position labeled Xq22. The PLP1 gene provides instructions for making two important proteins: proteolipid protein 1 itself and a modified version called DM20. These proteins are essential components of myelin, the fatty substance that wraps around nerve fibers and helps them transmit signals quickly and efficiently.[1]
The mutations that cause Pelizaeus-Merzbacher disease can take several different forms, and each type of mutation tends to produce different levels of disease severity. The most common cause, accounting for approximately 60 to 70 percent of cases, involves a duplication of the PLP1 gene. When this happens, the body produces too much of the proteolipid protein, which disrupts normal myelin formation. Other mutations involve changes in the gene’s DNA sequence that lead to abnormal proteins, or deletions where part or all of the gene is missing.[3][8]
When the PLP1 gene is duplicated, excessive amounts of proteolipid protein 1 and DM20 are produced. This excess protein becomes trapped within cells and cannot reach the cell membrane where it is needed to form myelin. In cases where mutations produce misfolded or abnormal proteins, these damaged proteins also accumulate inside cells, leading to swelling and eventual breakdown of nerve fibers. In deletion mutations, the lack of proteolipid protein makes any myelin that does form unstable and prone to rapid breakdown.[1]
Interestingly, up to 20 percent of males diagnosed with Pelizaeus-Merzbacher disease do not have mutations in the PLP1 gene. Some of these individuals have mutations in a different gene called GJC2, while others develop the disease for reasons that are not yet understood. This suggests that the disease may be more complex than initially thought, with multiple genetic pathways potentially leading to similar symptoms.[2]
Risk Factors
The primary risk factor for Pelizaeus-Merzbacher disease is having the genetic mutation that causes the condition. This disease follows an X-linked recessive inheritance pattern, which means it is passed down through families in a specific way. Males are at much higher risk of developing the disease because they have only one X chromosome. If that chromosome carries the mutated PLP1 gene, they will develop the condition since they have no second X chromosome to compensate.[3]
Females typically serve as carriers of the disease. They have two X chromosomes, so even if one carries the mutation, the other usually has a normal copy of the gene that can provide enough functional protein to prevent serious symptoms. However, female carriers can pass the mutated gene to their children. Each son born to a carrier mother has a 50 percent chance of inheriting the mutation and developing the disease, while each daughter has a 50 percent chance of becoming a carrier herself.[7]
Family history plays a crucial role in determining risk. Individuals with male family members who have been diagnosed with Pelizaeus-Merzbacher disease, or families with a pattern of unexplained neurological problems in males, may be at increased risk of carrying the genetic mutation. Mothers who have had one affected son have a high likelihood of having additional affected sons in future pregnancies.[3]
Symptoms
The symptoms of Pelizaeus-Merzbacher disease vary considerably depending on the specific type and severity of the condition, but they all stem from the nervous system’s inability to form adequate myelin. The disease is divided into two main types: classic and connatal, though there is also a milder form called spastic paraplegia type 2.[1]
Classic Pelizaeus-Merzbacher disease, the more common form, typically shows its first signs within a baby’s first year of life. Parents may notice that their infant has nystagmus, which appears as involuntary, rapid movements of the eyes from side to side. The baby may also have weak muscle tone, a condition called hypotonia, making them feel floppy when held. Developmental milestones such as sitting up, grasping objects, or holding the head steady are significantly delayed.[1]
As children with classic Pelizaeus-Merzbacher disease grow, they continue to develop new skills throughout childhood, though progress is slow compared to their peers. Some individuals may learn to walk with assistance, such as walkers or braces. Despite these physical challenges, many children can understand language and develop some ability to speak. However, development typically plateaus around adolescence, and these hard-won skills may gradually be lost over time in a process called developmental regression.[1]
The nystagmus that appears early in life usually disappears as the disease progresses, but it is replaced by other movement problems. These may include muscle stiffness called spasticity, problems with coordination and balance known as ataxia, trembling of the head and neck, involuntary muscle tensing called dystonia, and jerky, involuntary movements. These movement disorders significantly impact a person’s ability to control their body and perform daily activities.[1]
Connatal Pelizaeus-Merzbacher disease represents the more severe end of the spectrum. Symptoms begin in infancy and are more immediately life-threatening. Affected infants struggle with feeding, have difficulty gaining weight, and grow slowly. They may have breathing problems, including a high-pitched sound during breathing called stridor, which occurs when the airway is partially blocked. The nystagmus seen in classic cases also appears in connatal disease, along with severe lack of muscle tone and seizures.[1]
Children with connatal Pelizaeus-Merzbacher disease face severe limitations. They never develop the ability to walk independently, and many cannot purposefully use their hands or arms. While they have significant difficulty producing speech, they generally can understand what others say to them, indicating that their receptive language abilities remain relatively preserved even when expressive language is severely impaired. As the condition worsens, increasing spasticity leads to joint deformities called contractures that restrict movement even further.[1]
Prevention
Because Pelizaeus-Merzbacher disease is caused by genetic mutations present from birth, there are no lifestyle changes, vaccinations, or supplements that can prevent the disease from developing in someone who has inherited the mutation. However, families with a known history of the condition have several options to make informed decisions about family planning and potentially prevent passing the mutation to future generations.[3]
Genetic counseling serves as the first and most important step in prevention planning. A genetic counselor can help couples understand whether they carry the mutation, explain the chances of having an affected child, and discuss available testing options. This information empowers families to make choices that align with their values and circumstances.[11]
For families who know they carry the PLP1 mutation, prenatal testing offers a way to determine whether a pregnancy is affected by the disease. This testing can be performed through procedures such as amniocentesis or chorionic villus sampling, which analyze fetal cells for the presence of the genetic mutation. Knowing this information during pregnancy allows families to prepare for the care needs of an affected child or to consider their options.[11]
Preimplantation genetic diagnosis represents another option for carrier families who wish to have biological children. This technique is performed during in vitro fertilization, before embryos are placed in the uterus. Embryos created through IVF are tested for the PLP1 mutation, and only those without the mutation are selected for implantation. This approach allows carrier families to have children who will not be affected by the disease.[11]
Early identification of carriers within a family can be valuable. When one child is diagnosed with Pelizaeus-Merzbacher disease, genetic testing can determine whether the mother is a carrier and whether other female relatives might also carry the mutation. This knowledge helps extended family members make informed reproductive decisions and understand their own risks.[7]
Pathophysiology
Understanding the pathophysiology of Pelizaeus-Merzbacher disease requires understanding the crucial role that myelin plays in nervous system function. Myelin is a fatty substance that wraps around nerve fibers like insulation around electrical wires. This insulation allows electrical signals to travel rapidly along nerves, enabling quick communication between different parts of the brain, spinal cord, and body. When myelin is damaged or never forms properly, these signals slow down or stop entirely, causing the neurological symptoms seen in the disease.[6]
In Pelizaeus-Merzbacher disease, the problem is not that myelin is destroyed after forming normally, but rather that it never develops adequately in the first place. This condition is called hypomyelination, meaning there is a reduced ability to form myelin from the start. The disease belongs to a group of conditions called leukodystrophies, which specifically affect the white matter of the nervous system. White matter gets its color from myelin and consists primarily of nerve fibers traveling between different brain regions.[1]
The specific changes at the cellular level depend on the type of PLP1 mutation present. In cases where the gene is duplicated, cells produce excessive amounts of proteolipid protein 1 and DM20. This overproduction overwhelms the cell’s normal protein processing systems. The excess proteins accumulate inside cells rather than being incorporated into myelin at the cell membrane. These trapped proteins cause cellular stress, swelling, and eventual damage to the cells that make myelin, called oligodendrocytes.[1]
When mutations produce abnormal or misfolded versions of proteolipid protein, the cellular machinery recognizes these proteins as defective. The misfolded proteins accumulate within cell structures, triggering stress responses and preventing normal myelin formation. Over time, this accumulation damages oligodendrocytes and interferes with their ability to support and insulate nerve fibers.[1]
In deletion mutations where the PLP1 gene is partially or completely missing, cells cannot produce enough proteolipid protein 1 and DM20. Since these proteins make up the majority of myelin and help anchor it to cells, their absence means that any myelin that does form is structurally unstable. This unstable myelin breaks down quickly, leaving nerve fibers exposed and unable to transmit signals effectively.[1]
The white matter abnormalities in Pelizaeus-Merzbacher disease can be visualized through brain imaging, particularly magnetic resonance imaging (MRI). These scans typically show areas of high signal intensity throughout the brain’s white matter, appearing as bright regions on certain types of MRI sequences. These bright areas indicate regions where myelin is deficient or absent. These changes are usually evident by about one year of age in most cases, though subtle abnormalities may be visible even earlier in infancy.[4]
The progressive nature of the disease reflects ongoing problems with myelin maintenance and nerve fiber function. As affected individuals age, the cumulative effects of poor myelination become more apparent. Nerve fibers that lack proper myelin insulation cannot function efficiently, leading to the worsening neurological symptoms observed over time. The development that occurs during childhood represents the nervous system’s attempts to compensate for inadequate myelin, but these compensatory mechanisms eventually fail, leading to the developmental regression seen in many patients.[1]
